{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"CBR: percentage of participants with response of at least (SD for \\>=3 months or better sCR, iCR, mCR, CR, very good partial response \\[VGPR\\], PR, minimal response \\[MR\\] or SD) per investigator assessment by IMWG. sCR: CR plus normal FLC ratio, absence of clonal cells in BM. iCR: sCR plus absence of phenotypical aberrant plasma in BM with minimum of 1 million total BM cells. mCR: CR plus negative allele-specific oligonucleotide polymerase chain reaction. CR: Negative immunofixation on serum, urine, disappearance soft tissue plasmacytomas, \\<5% plasma cells in BM. VGPR: Serum, urine M-protein detectable by immunofixation but not on electrophoresis or \\>90% reduction in serum M-protein+urine M-protein level \\<100mg/24h. PR: \\>50% reduction of serum M-protein and in 24h urinary M-protein by \\>90% or to \\<200mg/24h. MR:\\>=25% but \\<=49% reduction in serum M-protein, reduction in 24h urine M-protein by 50 to 89%. SD: No CR, VGPR, PR or PD.","groups":[{"description":"Participants were planned to receive TAK-981 recommended phase 2 dose (RP2D), infusion, intravenously, in combination with an anti-CD38 antibody (mezagitamab or daratumumab and hyaluronidase-fihj), injection, subcutaneously, for up to 24 cycles or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 2: TAK-981 (RP2D) + Selected Anti-CD38 Antibody"}],"populationDescription":"The study was terminated after completion of Phase 1b Part 1, therefore, no participants were enrolled in Phase 2 part of the study. Hence, the data for this outcome measure could not collected, analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Phase 2: CBR Based on IMWG Criteria","type":"SECONDARY"}